This company has been marked as potentially delisted and may not be actively trading. NASDAQ:OASM Oasmia Pharmaceutical AB (publ) (OASM) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsTrendsBuy This Stock About Oasmia Pharmaceutical AB (publ) Stock (NASDAQ:OASM) 30 days 90 days 365 days Advanced Chart Get OASM alerts:Sign Up Key Stats Today's Range$0.02▼$0.0250-Day Range$1.30▼$1.6252-Week Range$0.94▼$5.70VolumeN/AAverage Volume98,414 shsMarket Capitalization$1.50 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewOasmia Pharmaceutical AB engages in the research and development of drugs. It formulates pharmaceutical products for ovarian and breast cancer for humans and cancer for animals. The company was founded by Julian Aleksov and Bo Cederstrand on April 15, 1988 and is headquartered in Uppsala, Sweden.Read More… Receive OASM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oasmia Pharmaceutical AB (publ) and its competitors with MarketBeat's FREE daily newsletter. Email Address OASM Stock News HeadlinesDouble Bond Pharmaceutical International AB (DBPHAb)October 31, 2024 | investing.comSector-Health Care & PharmaceuticalsMay 17, 2024 | newsweek.comWashington Is Broke—and Eyeing Your Savings NextWashington is running out of money…And guess where they'll look next? When governments go broke, they take from the people. It's happened before, and it's happening again. The Department of Justice just admitted that cash isn't legally YOUR property.May 22, 2025 | Priority Gold (Ad)BOEUF Bonesupport Holding AB (publ)April 30, 2024 | seekingalpha.comLipigon Pharmaceuticals AB LPGOMarch 23, 2024 | morningstar.comLSK BioPartners, Inc., Oasmia Pharmaceutical AB (publ) - Special Call TranscriptMarch 6, 2024 | gurufocus.comOasmia Pharmaceutical AB (publ) - Special Call TranscriptMarch 6, 2024 | gurufocus.comResurs Holding AB (publ) (RESURS.ST)February 8, 2024 | finance.yahoo.comSee More Headlines OASM Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Oasmia Pharmaceutical AB (publ) own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oasmia Pharmaceutical AB (publ) investors own include Protalix BioTherapeutics (PLX), Amarin (AMRN), Bristol-Myers Squibb (BMY), CRISPR Therapeutics (CRSP), Supernus Pharmaceuticals (SUPN), VBI Vaccines (VBIV) and Verastem (VSTM). Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:OASM CIK1607245 Webwww.oasmia.com Phone(461) 850-5440FaxN/AEmployees57Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,950,000.00 Net Margins-8,633.64% Pretax MarginN/A Return on Equity-43.94% Return on Assets-28.92% Debt Debt-to-Equity RatioN/A Current Ratio0.80 Quick Ratio0.73 Sales & Book Value Annual Sales$220,000.00 Price / Sales6.82 Cash FlowN/A Price / Cash FlowN/A Book Value$0.63 per share Price / Book0.03Miscellaneous Outstanding Shares74,967,000Free FloatN/AMarket Cap$1.50 million OptionableNot Optionable Beta0.96 10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:OASM) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersWarning: Prepare to Be Shocked by These PayoutsThere's a strategy out there paying up to 70% on tech stocks like Amazon, Tesla, and Microsoft—stocks that don...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery I think Trump’s Treasury Secretary is destroying the stock market on purpose. And no one on Wall Street see...Porter & Company | Sponsored🚨 Nvidia Just Inked a $7B AI Deal—This Could Change EverythingOn Wednesday, Nvidia stock surged—again. Why? Because Saudi Arabia just announced a multi-billion-dollar AI...Timothy Sykes | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oasmia Pharmaceutical AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Share Oasmia Pharmaceutical AB (publ) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.